Skip to main content

Table 3 Percentage footpad swelling (%fs) (delayed-type hypersensitivity reaction) to BSA or 18 kDa-hsp M. leprae antigens supported on DODAB-covered silica particles, or complexed with Al(OH3).

From: Silica-based cationic bilayers as immunoadjuvants

Systems for sensitization

Ag/dose for sensitization (μg/mouse)

Elicitation (μg/mouse)(i)

  

BSA

18 kDa-hsp M. leprae

  

4

40

3

30

  

% footpad swelling ± SEM

Silica/DODAB(ii)

-

2 ± 2

2 ± 2

-

-

BSA

10

2 ± 2

2 ± 2

-

-

Silica/BSA(ii)

10

3 ± 2

2 ± 2

-

-

DODAB BF(iii)/BSA

10

3 ± 2

2 ± 2

-

-

Silica/DODAB/BSA(ii)

10

11 ± 2(iv)

14 ± 4(iv)

-

-

18 kDa-hsp M. leprae

15

-

-

4 ± 2

10 ± 2

DODAB BF(iii)/18 kDa-hsp

15

  

56 ± 8(iv), (v)

95 ± 16(iv), (v)

Silica/DODAB/18 kDa-hsp(ii)

15

-

-

60 ± 7(iv), (v)

89 ± 8(iv), (v)

Al(OH)3/18 kDa-hsp(ii)

15

-

-

18 ± 4(iv)

33 ± 1(iv)

  1. (i) Animals were sensitized with different systems and footpad swelling was elicited on the 5th day pos-immunization.
  2. (ii) Silica at final concentration of 0.1 mg/ml; DODAB at final concentration of 0.05 mM. Al(OH)3 at final concentration of 0.1 mg/ml.
  3. (iii) [DODAB] = 0.1 mM.
  4. (iv) P < 0.05, compared to animals that were BSA or 18 kDa-hsp M. leprae-pretreated and received the same elicitation dose.
  5. (v) P < 0.05, compared to animals that were Al(OH3)/18 kDa-hsp-pretreated and received the same elicitation dose.
Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us